Noxopharm Ltd has released a press release.
December 2024 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Additional convertible note for long-term shareholder
- September 2024 Quarterly Activities report and Appendix 4C
- New funding from sophisticated investors
- Advanced funding secured ahead of R&D rebate
- Significant results from new brain cancer drugs
Later from Noxopharm
- SOF-SKN passes required in vitro safety tests
- Appendix 4D and FY2025 Half Year Financial Report
- March 2025 Quarterly Activities Report and Appendix 4C
- New funds from Nyrada share sales
- Green light for HERACLES clinical trial
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm